Bahrain extends support program for businesses hit by coronavirus    UK Minister for South Asia Lord Ahmad concludes 2-day visit to Pakistan    Over 60% of UK adults receive both doses of COVID-19 vaccine    KSrelief's Clinics Provide Medical Services for 570 Individuals in Zaatari Camp, Jordan    Wall Street Closing    Pedestrian bridge collapses onto Washington, DC, highway, injuring several    US voices 'grave concern' after airstrike kills dozens at market in Ethiopia's Tigray region    John McAfee, antivirus software creator, found dead in Spanish prison    Small businesses unprepared for pandemic-sized climate shock 'every decade'    Saudi Arabia's localization of military industries offers breadth of opportunities to US investors: GAMI governor    Bahrain Two Main Indexes End Trading Up    Backed by KSrelief, Al-Jaada Health Center Provides Services for 1,861 Beneficiaries During One Week    Pakistan Records 930 New COVID-19 Cases    SAGO Receives First Vessel of Wheat Produced by Saudi Investment Abroad    Over 15 Million Zamzam Water Bottles Distributed at Grand Holy Mosque    HRC President Meets with Chief of OHCHR MENA Section    Chairman and CEO of STC Thank Saudi Leadership for Licensing STC Bank as First Digital Bank in Saudi Arabia    Saudi national team wins 2 gold medals at Arab Athletics Championship    Tawakkalna's Update Includes New Hajj, SOS Services    Saudi National Team Wins 2 Gold Medals at Arab Athletics Championship    Judge, officials and others arrested in corruption crackdown    Saudi Press: Saudi Arabia Achieves Highest Level in Digital Regulatory Maturity Index    HRC official highlights measures to support prisoners and families    Bahrain Condemns Terrorist Houthi Militia's Launching of Drone towards Khamis Mushait    Al-Sheikh underlines importance of preparing young generation for future jobs in G20 ministerial meeting    Dubai opens one of the world's largest in-house airport PCR test labs    Saudi foreign minister, Austrian counterpart discuss ways to boost bilateral ties    Tokyo Olympics: Limited local fans allowed to attend but no cheering    Saudi, Indian ministries sign historic MoU on yoga cooperation    Minister of Sports unveils 'Nafes' platform to boost private sector investment in Saudi Arabia    RSIFF celebrates Saudi Cinema Nights in Jeddah on June 16–17    "Scripts and Calligraphy: A Timeless Journey" Exhibition Begins to Receive Visitors Today    $10 million Red Sea Fund to back over 100 projects    Saudi Music Commission Dedicates Patriotic Song to Green Falcons    Indian man believed to have headed 'world's largest family' dies    Ministry of Health: People With Obesity are Most Vulnerable to COVID-19 Infections    Saudi National Team Beats Singaporean Counterpart 3-0 in FIFA World Cup 2022 and AFC Asian Cup 2023 Qualifiers    Saudi National Shooting Team Wins Gold, Silver Medals in Arab Shooting Championship    Saudi U-20 Team Beats Bosnia at End of Croatian Tournament    Ithra Holds Environment Exhibit    Use of external loudspeakers at mosques to be restricted to Adhan and Iqamat-ul-salah    From whom do we take Shariah? How do we get legitimacy?    Welcome to beautiful Ramadan customs    Vaccination does not invalidate fasting, says UAE Fatwa Council    Council of Senior Scholars: Muslim Brothers' Group Don't Represent Method of Islam, rather only Follows its Partisan Objectives, Violating our Graceful Religion    Eid Al-Adha Prayer Performed at the Grand Holy Mosque    Pilgrims Perform Dhuhr and Asr Prayers in Arafat Holy Site    Senior Scholars Council Issues Decision No. 246 Regarding Attendance of Friday Prayer and Prayers at Mosques in a Case of Spread of Epidemic or Fear of its Spread    

Thank you for reporting!
This image will be automatically disabled when it gets reported by several people.

Superbug threat prompts West to revisit Soviet-era virus therapy
Published in The Saudi Gazette on 04 - 07 - 2015

Ben Hirschler

ALARMED by rising resistance to antibiotics, the main line of defense against bacterial infections, scientists and governments are taking a fresh look at bacteria-chomping viruses first isolated a century ago from the stools of patients recovering from dysentery.
So-called bacteriophages, which attack bacteria but leave human cells unscathed, are still used in Russia, Georgia and Poland, but fell by the wayside in the West with the mass production of penicillin, the first antibiotic, in the 1940s.
Now, faced with the rise of drug-resistant “superbugs” such as MRSA or multi-drug-resistant tuberculosis, and a World Health Organization warning that a “post-antibiotic era” is dawning, European and US researchers and authorities are thinking again.
The first major multi-center clinical trial of phage therapy, funded by the European Commission, will start treating French, Belgian and Swiss burns patients with infections in the next few days.
And last month, the European Medicines Agency hosted its first workshop on bacteriophages to discuss how the technology should be regulated and used.
“We need alternatives to the current armamentarium of antibiotics and we want to see more development activity in this area,” Marco Cavaleri, the agency's head of anti-infectives and vaccines, told Reuters.
“In light of the increase in antimicrobial resistance and the lack of new antibiotics, it is important to open up the discussion.”
Across the Atlantic, the US National Institute of Allergy and Infectious Diseases is also convening a conference on phage therapy this month, having identified it in 2014 as one of seven key areas in the fight against antibiotic resistance.
It's not that the West has completely ignored the potential of phages until now. In the 1930s, drug makers including Eli Lilly and E.R. Squibb made therapeutic phage preparations, and a phage product from Dutch firm Micreos has been used in Europe and the United States since 2006 to prevent listeria in food.
But phage therapy has never been tested in the clinic to the rigorous standards of Western medicine, as doctors have opted for tried and tested antibiotics.
Soviet doctors, by contrast, were deprived of access to early Western antibiotics and turned to phage therapy for everything from gastrointestinal infections to battlefield wounds.
Today, Russia's Microgen remains a leading supplier of bacteriophages, while the Eliava Institute in Tbilisi, Georgia, has been a center of phage expertise since 1923 and EU member state Poland still offers phage therapy, albeit for “compassionate use” only, because it lacks EU approval.
Phages kill bacteria by getting into bacterial cells and replicating — but the lack of hard data means their effectiveness and safety as a treatment is unclear.
The new 220-patient clinical trial known as Phagoburn, which has 3.8 million euros ($4.2 million) of EU funding, aims to close that knowledge gap — although Cavaleri believes it will still be at least five years before any product meeting stringent Western drug standards is ready for approval.
Jerome Gabard, chief executive of French biotech firm Pherecydes Pharma, which makes the phage cocktail used in the Phagoburn trial, hopes he might get a conditional green light before that, but acknowledges Western doctors will be wary.
“This will probably be a last-resort treatment, after three or four lines of antibiotics have been tried,” he said. “It will be for fighting multi-drug resistant strains that are not cured by antibiotics.”
That points to a niche market and Gabard says his company's phage therapy will probably cost between 2,000 and 7,000 euros per treatment.
There are plenty of hurdles ahead, including a need to quell public concerns about using live viruses, even if they are harmless to mammalian cells.
Regulators will also have to work out how to oversee a therapy that consists of a combination of multiple wild phage strains that will change over time.
It may be that phage therapy is treated in a similar way to seasonal flu vaccines, which are adapted each year as flu evolves.
So far, only a few biotech companies are investing in the field, with Pherecydes' rivals including US firms AmpliPhi Biosciences and Intralytix, Britain's Novolytics, Portugal's Technophage and China's Phagelux.
Large drug makers have so far remained on the sidelines, partly because of uncertainty about the ability to patent a technology that uses naturally occurring viruses and is nearly a century old.
Mark Fishman, head of research at Novartis, for example, told Reuters the Swiss drug maker was not currently looking at phage therapy since it still saw considerable potential for developing new antibiotics.
French critical care doctor Patrick Jault, one of the coordinators of the Phagoburn study, believes all options should be explored - but whatever the results of the current clinical trial, further studies will be necessary. “This is just the start,” he said. — Reuters

Clic here to read the story from its source.